Navigation Links
Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Date:8/27/2007

-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to

Upstream-

-Initial Compounds Demonstrate Promising In Vitro Activity Against Devastating Parasitic Diseases Affecting 300 Million People Worldwide-

VANCOUVER, B.C., Aug. 27 /PRNewswire-FirstCall/ -- Upstream Biosciences Inc. (OTC Bulletin Board: UPBS) today announced it has completed the acquisition of Pacific Pharma Technologies Inc., an early stage biopharmaceutical company with a proprietary technology platform that combines artificial intelligence, advanced computational methods and chemical diversity techniques to discover new drugs. This technology has already generated novel compounds that in laboratory studies demonstrate both human and veterinary potential against major tropical parasitic diseases.

"This acquisition significantly broadens our strategic focus and provides Upstream with important new capabilities," said Joel L. Bellenson, Chief Executive Officer of Upstream. "We believe the innovative technology platform pioneered by Pacific Pharma may have substantial commercial potential in a number of therapeutic areas and it fits well with our existing core competencies in computational-based approaches to biomarker identification. Pacific Pharma has also generated novel compounds that have exhibited activity against targets relevant to cancer, the focus of our biomarker programs."

In screening studies in vitro, Pacific Pharma's lead compounds have demonstrated encouraging signs of efficacy against leishmaniasis and African sleeping sickness (trypanosomiasis). These parasites, which belong to a family of protozoa species that include Chagas disease and malaria, infect millions of individuals in Africa, South Asia and South America. Current treatments are often toxic, ineffective, inconvenient and expensive. In addition, recent reports document
'/>"/>

SOURCE Upstream Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , October 24, 2014 ... has announced the addition of the "Global ... report to their offering.      (Logo: ... Concentrates Industry Report 2014 is a professional and ... hemodialysis concentrates industry with a focus on the ...
(Date:10/25/2014)... HOUSTON , Oct. 24, 2014   Metanome, ... of comprehensive metagenomic services and data analysis, was the ... Mass ) Phase I/II clinical trial of SER ... with recurrent Clostridium difficile infections (CDI). ... of Seres Health,s R&D and clinical programs. Such genomic ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
... , MORRISTOWN, N.J. , May 7 Watson Pharmaceuticals, ... Laboratories, Inc. has reached a settlement with Teva Women ,s Health, ... estradiol tablets USP, 0.15 mg/0.03 mg) product. , ... On December 13, 2007 , Teva filed a ...
... , May 7 Patients treated ... clinical improvement at two years, according to interim ... today as a late-breaking clinical trial at the ... Annual Scientific Sessions. The prospective, single-arm study is ...
Cached Medicine Technology:Watson Reaches Settlement with Teva Over Seasonale(R) 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:10/25/2014)... The global HCIT outsourcing market is forecast ... $50.4 billion by 2018 from $35 billion in 2013. ... industry are driving the HCIT outsourcing market. These industries ... on core business, reduce operational and maintenance costs, increase ... hiring and training costs), share risk, and quickly implement ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/22/2014)... At a time when the national concussion ... at all levels, the UPMC Sports Medicine Concussion ... where two powerful messages are lost: Concussions can be ... full recoveries every day. , In striving to shift ... research, UPMC and the Concussion Program are unveiling the ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... ... The VitaLogikTM 6000 is a pre-configured multi-parameter Patient Monitor with ... uninterrupted vital signs, monitoring. An integrated wireless local area network solution ... new propriety internal wireless card and based on the IEEE Compliance ...
... ... the launch of the EliteCustom® Vacuum Therapy System as a conservative treatment option ... ... announces a new Vacuum Therapy Supply Program with the launch of the EliteCustom® ...
... ... ... 22, 2010 -- Aprima Medical Software , a leading developer of electronic health ... reseller agreement with Pacific Medical IT Inc., a California-based leader in providing local medical ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... enhances customer service and Web site features with online customized health plan quotes , ... Chicago, IL (PRWEB) February 22, 2010 ... health insurance, introduces a new Web tool for customized health plan quotes. With a few ...
... , ... ... ... ...
Cached Medicine News:Health News:Mennen Medical Launches the VitaLogik 6000, a Pre-Configured Multi-Parameter Patient Monitor with New High Performance Wireless Technology 2Health News:Mennen Medical Launches the VitaLogik 6000, a Pre-Configured Multi-Parameter Patient Monitor with New High Performance Wireless Technology 3Health News:Home Care Delivered, Inc. Launches a New Vacuum Therapy Category to Service Patients with Erectile Dysfunction 2Health News:Home Care Delivered, Inc. Launches a New Vacuum Therapy Category to Service Patients with Erectile Dysfunction 3Health News:Aprima and Pacific Medical IT Partner to Provide Electronic Health Records to Physician Practices 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:Leading Chicago Insurance Company, JMW & Sons, Introduces Online Tool for Customized Health Plan Quotes 2Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 2Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 3Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 4Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 5Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 6Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 7Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 8Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 9Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 10Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 11Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 12
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... a fast, precise patternless edge for a ... TOPCON ALE-X1. The latest advance in lens ... features and functions. High-speed processing, a diamond ... edges, precise three-dimensional frame tracing via the ...
Inquire...
Inquire...
Medicine Products: